Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...

Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved cabozantinib for patients 12 years of age and older ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

“The COMPETE results represent a major step forward in the development of new treatment options for people living with progressive, inoperable GEP-NETs,” Dr Jonathan Strosberg, past president, North ...

It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and ...

Appendix tumors should be evaluated separately and not included in colon or colorectal cancer categories,” researchers concluded.